Phase 3 Randomized, Double-blind, Placebo-controlled Studies Assessing Ziftomenib in Combination with Either Standard of Care Nonintensive (Venetoclax+Azacitidine) or Intensive (7+3) Therapy in Patients with Untreated NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia

Trial information

Medical condition

Untreated AML

Trial phase

Phase 3

Sponsor

Kura Oncology, Inc.

Start date

30/03/2026

End date

30/09/2030

Main objective

CR and OS

Locations and Contact points